Surgical Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Transl Vis Sci Technol. 2024 Sep 3;13(9):15. doi: 10.1167/tvst.13.9.15.
To determine the effect of telmisartan on intraocular pressure (IOP), blood pressure (BP), and ocular perfusion pressure (OPP) in normal and glaucomatous cats.
A four-week study was conducted in six normal adult cats, followed by a longer six-month study performed in 37 cats with spontaneous glaucoma and 11 age-matched normal cats. Telmisartan (1 mg/kg/day) or placebo-vehicle were administered orally once daily. IOP was measured by rebound tonometry. BP readings were obtained by oscillometric method. OPP was calculated as mean arterial pressure (MAP) - IOP. IOP and BP were obtained three times a week for the first study and weekly for the second study.
Baseline IOP was significantly higher, and OPP was significantly lower in glaucomatous cats than in normal cats (P < 0.0001). These differences between glaucomatous and normal cats persisted throughout the study, regardless of treatment (P < 0.001). No significant differences in IOP, BP, or OPP were detected between any study phases in the first, normal feline cohort or between telmisartan- and placebo-treated glaucomatous cats at any timepoint in the second study.
Oral telmisartan was well tolerated and did not have a detrimental effect on BP or OPP in cats but did not lower IOP or improve OPP in cats with glaucoma.
While showing telmisartan could not be used as a sole therapy for IOP lowering, our data affirmed a lack of detrimental effects of telmisartan on BP and OPP in a translationally-relevant, spontaneous, large animal glaucoma model.
观察替米沙坦对正常猫和青光眼猫眼压(IOP)、血压(BP)和眼灌注压(OPP)的影响。
在 6 只正常成年猫中进行了为期 4 周的研究,随后在 37 只自发性青光眼猫和 11 只年龄匹配的正常猫中进行了为期 6 个月的研究。替米沙坦(1mg/kg/天)或安慰剂载体通过口服给药,每天一次。通过回弹眼压计测量 IOP。通过振荡法测量 BP 读数。OPP 计算为平均动脉压(MAP)-IOP。在第一项研究中,每周测量三次眼压和血压,在第二项研究中每周测量一次。
与正常猫相比,青光眼猫的基线 IOP 显著升高,OPP 显著降低(P<0.0001)。无论治疗如何,这些青光眼猫和正常猫之间的差异在整个研究过程中都持续存在(P<0.001)。在第一项正常猫队列的任何研究阶段,以及在第二项研究中任何时间点的替米沙坦和安慰剂治疗的青光眼猫之间,都未检测到 IOP、BP 或 OPP 有显著差异。
口服替米沙坦耐受性良好,对猫的 BP 或 OPP 没有不良影响,但不能降低青光眼猫的 IOP 或改善 OPP。
虽然表明替米沙坦不能单独用于降低 IOP,但我们的数据证实了替米沙坦在一种转化相关的、自发性的大动物青光眼模型中对 BP 和 OPP 没有不良影响。